Details for New Drug Application (NDA): 211857
✉ Email this page to a colleague
NDA 211857 describes VASOPRESSIN, which is a drug marketed by Am Regent, Amneal, Amphastar Pharms Inc, Cipla, Dr Reddys, Eagle Pharms, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Baxter Hlthcare Corp, and Long Grove Pharms, and is included in eleven NDAs. It is available from ten suppliers. Additional details are available on the VASOPRESSIN profile page.
The generic ingredient in VASOPRESSIN is vasopressin. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
The generic ingredient in VASOPRESSIN is vasopressin. There are nine drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the vasopressin profile page.
Summary for 211857
| Tradename: | VASOPRESSIN |
| Applicant: | Amphastar Pharms Inc |
| Ingredient: | vasopressin |
| Patents: | 0 |
Pharmacology for NDA: 211857
| Physiological Effect | Decreased Diuresis Vasoconstriction |
Suppliers and Packaging for NDA: 211857
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| VASOPRESSIN | vasopressin | SOLUTION;INTRAVENOUS | 211857 | ANDA | Amphastar Pharmaceuticals, Inc. | 0548-9701 | 0548-9701-00 | 1 VIAL in 1 CARTON (0548-9701-00) / 1 mL in 1 VIAL |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAVENOUS | Strength | 20UNITS/ML (20UNITS/ML) | ||||
| Approval Date: | Jul 18, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
